{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:25:48Z","timestamp":1786119948398,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1097\/mjt.0b013e31820b8668","type":"journal-article","created":{"date-parts":[[2011,4,26]],"date-time":"2011-04-26T03:53:05Z","timestamp":1303789985000},"page":"337-343","source":"Crossref","is-referenced-by-count":4,"title":["Ideal Antiplatelet Therapy for Coronary Artery Disease"],"prefix":"10.1097","volume":"20","author":[{"given":"Suraj","family":"Chandrasekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parinda","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210202","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":". A clinical trial comparing three antithrombotic-drug regimens after coronary artery stenting.","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"key":"R2-5-20210202","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/hrt.2005.071209","article-title":"Antiplatelet treatment for coronary heart disease.","volume":"93","author":"Clappers","year":"2007","journal-title":"Heart"},{"key":"R3-5-20210202","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood.V92.5.1518","article-title":". A double blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans.","volume":"92","author":"Jean-Pierre","year":"1998","journal-title":"Blood"},{"key":"R4-5-20210202","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1026551409350","article-title":"Leone, et al.. Ticlopidine and aspirin fail to suppress the increased platelet aggregability that follows percutaneous coronary interventions.","volume":"10","author":"Fischetti","year":"2000","journal-title":"J Thromb Thrombolysis"},{"key":"R5-5-20210202","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s002770050369","article-title":". Ticlopidine-associated aplastic anemia.","volume":"76","author":"Yeh","year":"1998","journal-title":"Ann Hematol"},{"key":"R6-5-20210202","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11886-008-0052-y","article-title":"Antiplatelet therapy in acute coronary syndromes.","volume":"10","author":"Colin","year":"2008","journal-title":"Curr Cardiol Rep"},{"key":"R7-5-20210202","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1161\/01.CIR.99.18.2364","article-title":". Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.","volume":"99","author":"Issam","year":"1999","journal-title":"Circulation"},{"key":"R8-5-20210202","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/01.CIR.101.6.590","article-title":". A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents.","volume":"101","author":"Christian","year":"2000","journal-title":"Circulation"},{"key":"R9-5-20210202","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"R10-5-20210202","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial.","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"R11-5-20210202","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.","volume":"354","year":"2006","journal-title":"N Engl J Med"},{"key":"R12-5-20210202","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double blind, placebo-controlled trial.","volume":"364","year":"2004","journal-title":"Lancet"},{"key":"R13-5-20210202","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"R14-5-20210202","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","article-title":". Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.","volume":"301","author":"Michael","year":"2009","journal-title":"JAMA"},{"key":"R15-5-20210202","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/hrt.2009.171488","article-title":". Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.","volume":"96","author":"Thomas","year":"2010","journal-title":"Heart"},{"key":"R16-5-20210202","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events.","volume":"360","year":"2009","journal-title":"N Engl J Med"},{"key":"R17-5-20210202","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/eurheartj\/ehi877","article-title":". Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin treated patients with stable coronary artery disease.","volume":"27","author":"Jernberg","year":"2006","journal-title":"Eur Heart J"},{"key":"R19-5-20210202","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/j.1538-7836.2007.02598.x","article-title":". The greater in vivo antiplatelet effects of prasugrel as compared to Clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrels active metabolite.","volume":"5","author":"Sugidachi","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"4","key":"R20-5-20210202","first-page":"421","article-title":". A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans.","volume":"63","author":"Joseph","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"R21-5-20210202","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes.","volume":"357","year":"2007","journal-title":"N Engl J Med"},{"key":"R22-5-20210202","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","article-title":". Common polymorphisms of CYP2C19 and CYP2C9 affect pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.","volume":"5","author":"Brandt","year":"2007","journal-title":"J Thrombosis Haemost"},{"key":"R23-5-20210202","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00228-009-0778-5","article-title":"Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects.","volume":"66","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"R24-5-20210202","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes.","volume":"361","year":"2009","journal-title":"New Engl J Med"},{"key":"R27-5-20210202","first-page":"2","article-title":". Genotyping: one piece of the puzzle to personalize antiplatelet therapy.","volume":"56","author":"Paul","year":"2010","journal-title":"J Am Coll Cardiol"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00045391-201307000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:29:24Z","timestamp":1786044564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045391-201307000-00005"}},"subtitle":["Focus on Adenosine Diphosphate Receptor Inhibitors"],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e31820b8668","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}